AlphaCentric Advisors LLC Buys 5,000 Shares of Immatics (NASDAQ:IMTX)

AlphaCentric Advisors LLC raised its stake in shares of Immatics (NASDAQ:IMTX) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 25,000 shares of the company’s stock after purchasing an additional 5,000 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Immatics were worth $285,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in IMTX. Quarry LP bought a new position in shares of Immatics during the 2nd quarter worth about $99,000. Forefront Analytics LLC bought a new stake in Immatics in the second quarter valued at about $139,000. Nan Fung Group Holdings Ltd bought a new stake in Immatics in the first quarter valued at about $165,000. Algert Global LLC bought a new stake in Immatics in the second quarter valued at about $242,000. Finally, XTX Topco Ltd bought a new stake in Immatics in the second quarter valued at about $321,000. Institutional investors own 64.41% of the company’s stock.

Immatics Stock Up 0.2 %

Shares of Immatics stock opened at $9.35 on Tuesday. Immatics has a 1-year low of $7.98 and a 1-year high of $13.77. The firm’s 50-day moving average price is $10.76 and its two-hundred day moving average price is $11.34.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.17. The firm had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. Research analysts anticipate that Immatics will post -0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IMTX has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a research note on Thursday, September 5th. Piper Sandler initiated coverage on shares of Immatics in a research note on Monday, October 7th. They issued an “overweight” rating and a $19.00 target price on the stock.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.